All In Biotech

Drug Trial Radar · NCT04809818

A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects

Double-Blind, Randomized, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of LT3001 Drug Product and Drug-Drug Interaction in Healthy Adult Subjects

Last checked: Nov 19, 2026Latest source record: Mar 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

65

Actual

Start

Mar 21, 2021

Primary completion

Aug 5, 2021

Study completion Aug 5, 2021

Sponsor

Lead sponsor
Lumosa Therapeutics Co., Ltd.Industry
Sponsor type
Industry
First posted
Mar 22, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This Phase 1 study is planned to establish the clinical safety and pharmacokinetics profile of multiple dose of LT3001 drug product and to investigate drug interactions of LT3001 with potential concomitant medications in healthy subjects.

Conditions

  • Acute Ischemic Stroke

Interventions

  • LT3001 drug productDrug

    Multiple doses of LT3001 drug product administered by intravenous infusion

  • PlaceboDrug

    Multiple doses of Placebo administered by intravenous infusion

  • AspirinDrug

    Loading and maintenance doses of Aspirin administered by oral

  • ClopidogrelDrug

    Loading and maintenance doses of Clopidogrel administered by oral

  • ApixabanDrug

    Multiple doses of Apixaban administered by oral

  • DabigatranDrug

    Multiple doses of Dabigatran administered by oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Adverse EventsTime frame: Adverse events were assessed from baseline through Day 4 post-baseline in Part A, and from baseline through Day 16 post-baseline in Part B.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Lumosa Phase 1 Unit

    Cypress, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.